Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.52 |
| ▸ | NAMPT | P43490 | 4/20 | 0.47 |
| ▸ | BRD4 | O60885 | 3/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3769645 | 0.85 | MAPK1 (0.63) | MAPK1CRBNDDB1NAMPTBRD4 | |
| SCHEMBL18464821 | 0.85 | BRD4 (0.47) | MAPK1BRD4CREBBPAHRPDK2 | |
| SCHEMBL5183098 | 0.82 | MAPK1 (0.64) | MAPK1CRBNDDB1NAMPTNR1H2 | |
| SCHEMBL29676965 | 0.82 | MAPK1 (0.64) | MAPK1CRBNDDB1NAMPTNR1H2 | |
| SCHEMBL2359709 | 0.82 | CRBN (0.47) | MAPK1CRBNDDB1BRD4CREBBP | |
| SCHEMBL6779500 | 0.82 | CRBN (0.50) | MAPK1CRBNDDB1BRD4CREBBP | |
| SCHEMBL21257573 | 0.82 | CRBN (0.47) | MAPK1CRBNDDB1BRD4CREBBP | |
| SCHEMBL3425986 | 0.82 | CRBN (0.50) | MAPK1CRBNDDB1BRD4CREBBP | |
| SCHEMBL21798833 | 0.81 | MAPK1 (0.44) | MAPK1CRBNDDB1NAMPTBRD4 | |
| SCHEMBL1583251 | 0.81 | DDB1 (0.47) | MAPK1CRBNDDB1NR1H2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024163956-A2 | SIGMA RECEPTOR LIGAND COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-08-08 | — | — | WO | disclosed |
| EP-3782996-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-04-10 | — | — | EP | disclosed |
| US-20230047296-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| US-20230047296-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| EP-3782996-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-02-24 | — | — | EP | disclosed |
| EP-3782996-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-02-24 | — | — | EP | disclosed |
| EP-3307739-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| EP-3307739-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| US-10604509-B2 | Nrf2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-31 | — | — | US | disclosed |
| US-10604509-B2 | Nrf2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-31 | — | — | US | disclosed |
| US-8455479-B2 | Heterocyclic compounds | PANACEA BIOTEC LIMITED (IN) | 2013-06-04 | — | — | US | disclosed |
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC PHARMA LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| EP-2250157-A1 | NOVEL HETEROCYCLIC COMPOUNDS | Panacea Biotec Limited (IN) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009093269-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC LIMITED (IN) | 2009-07-30 | — | — | WO | disclosed |
| US-6825191-B2 | ANTICOAGULANT | AJINOMOTO CO., INC. (JP) | 2004-11-30 | — | — | US | disclosed |
| US-20030186969-A1 | Benzodiazepine derivatives | AJINOMOTO CO. INC (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1329450-A1 | BENZODIAZEPINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2003-07-23 | — | — | EP | disclosed |
| EP-0789571-A4 | CYCLIC AMIDINE ANALOGS AS INHIBITORS OF NITRIC OXIDE SYNTHASE | MERCK & CO INC (US) | 1999-04-14 | — | — | EP | disclosed |
| EP-0789571-A1 | CYCLIC AMIDINE ANALOGS AS INHIBITORS OF NITRIC OXIDE SYNTHASE | Merck & Co., Inc. (US) | 1997-08-20 | — | — | EP | disclosed |
| WO-1996014844-A1 | CYCLIC AMIDINE ANALOGS AS INHIBITORS OF NITRIC OXIDE SYNTHASE | MERCK & CO., INC. (US) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186969-A1 | Benzodiazepine derivatives | GABRA1, F11, GABRA4 | MAPK1 1817/4885CRBN 1309/4885DDB1 2932/4885 |
| US-10604509-B2 | Nrf2 regulators | NFE2L2, KEAP1, NQO1 | MAPK1 3174/4885CRBN 620/4885DDB1 414/4885 |
| US-20230047296-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | MAPK1 3198/4885CRBN 584/4885DDB1 618/4885 |
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DPP4, DPP3, DPP8 | MAPK1 2715/4885CRBN 4833/4885DDB1 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.